Description
Mirataz 20mg/g Transdermal Ointment
The active ingredient Mirtazapine is absorbed through the skin of the ear into the bloodstream. The effects of mirtazapine on weight gain are complex and not fully understood. They include blocking some of the actions of serotonin and histamine, substances involved in the regulation of appetite, and an effect on levels of leptin, a hormone that controls hunger.
Use this product as directed by your veterinary surgeon. You should carefully read all product packaging and labels prior to use.
The importance of treating poor appetite and weight loss resulting from chronic medical conditions in cats
Unintended feline weight loss may be associated with serious consequences;
- A Low Body Condition Score (BCS) is linked to reduced survival across many disease states
- Prolonged inadequate nutrition may be more detrimental to the patient than the primary disease process5
- In diseased cats a change in production of inflammatory cytokines, catecholamines, cortisol, insulin and glucagon can trigger a hyper-metabolic state, characterised by protein catabolism, cachexia, insulin resistance, lipolysis and increased energy expenditure
- Patients with cachexia may get into a negative nitrogen and energy balance, lose lean body mass and are at risk of developing malnutrition. Malnutrition can result in anaemia, hypoproteinaemia and reduced immune function, wound healing and organ function
- Poor appetite is emotionally distressing to owners and is perceived as an indication of poor quality-of-life
Mirataz is the first licensed veterinary medicinal product for body weight gain in cats experiencing poor appetite.
The active ingredient, mirtazapine, addresses reduced appetite and induces significant weight gain in as little as 14 days.
This can allow for a swift response to initial symptoms – improving condition and wellbeing before you have a definitive diagnosis, alongside providing support to patients already receiving long term treatment.
